+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chemotherapy-induced Nausea and Vomiting Drugs - Global Market Trajectory & Analytics

  • ID: 5309389
  • Report
  • April 2021
  • Region: Global
  • 134 pages
  • Global Industry Analysts, Inc
1 of 2
Global Chemotherapy-induced Nausea and Vomiting Drugs Market to Reach $3.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Chemotherapy-induced Nausea and Vomiting Drugs estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Neurokinin NK1 Receptor Antagonist segment is readjusted to a revised 5.8% CAGR for the next 7-year period.



The U.S. Market is Estimated at $667.6 Million, While China is Forecast to Grow at 4.8% CAGR

The Chemotherapy-induced Nausea and Vomiting Drugs market in the U.S. is estimated at US$667.6 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$565.6 Million by the year 2027 trailing a CAGR of 4.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.9% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Dopamine Antagonist Segment to Record 4.8% CAGR

In the global Dopamine Antagonist segment, USA, Canada, Japan, China and Europe will drive the 4.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$294.1 Million in the year 2020 will reach a projected size of US$409.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$368.2 Million by the year 2027.

Select Competitors (Total 41 Featured):
  • Acacia Pharma Group Plc
  • Aphios Corporation
  • Baxter International Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Especificos Stendhal S.A. DE C.V.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Lee's Pharmaceutical Holdings Ltd.
  • Merck & Co., Inc.
  • Midatech Pharma PLC
  • Mundipharma Pte., Ltd.
  • Mylan N.V.
  • Ono Pharmaceutical Co., Ltd.
  • Opko Health, Inc.
  • Orchid Chemicals & Pharmaceuticals Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • Purdue Pharma LP
  • Sandoz International GmbH
  • SciClone Pharmaceuticals, Inc.
  • Shin Nippon Biomedical Laboratories Ltd. (SNBL)
  • Solasia Pharma K.K.
  • Specialised Therapeutics Asia Pte Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Tesaro, Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
2 of 2
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Serotonin Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Neurokinin NK1 Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Dopamine Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Benzodiazepine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 19: USA Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: USA Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: USA 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 22: Canada Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 23: Canada Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: Canada 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 25: Japan Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Japan Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: Japan 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 28: China Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: China Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: China 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 31: Europe Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 32: Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 34: Europe Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 37: France Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: France Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: France 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 40: Germany Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Germany Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Germany 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 43: Italy Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Italy Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: Italy 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 46: UK Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: UK Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: UK 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 49: Rest of Europe Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Rest of Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: Rest of Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 52: Asia-Pacific Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: Asia-Pacific Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Asia-Pacific 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
  • Table 55: Rest of World Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Rest of World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: Rest of World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 41
Note: Product cover images may vary from those shown
Adroll
adroll